DIFFERENT DENDRITIC CELL SUBSETS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Mar 9, 2006
filing date -
Jan 16, 2003
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
It is intended to provide expired dendritic cells having characteristics of the following (E1) to (E3): (E1) not shifting into a mature type due to an action of a natural immune stimulant or a permanent immune potentiator; (E2) having the same shape as immature DC; and (E3) expressing IL-10. It is intended to provide Permanently activated dendritic cells having the following characteristics: (M2-1) having projecting dendrites and forming aggregation clusters; (M2-2) being capable of activating unreacted cytotoxic T cells (CTL); (M2-3) having stable properties under the action of anti-CD40 monoclonal antibody; and (M2-4) showing a high expression level of at least one member selected from the group consisting of CD80, CD83 and CD86.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully